 Palatin Technologies Inc NYSE: PTN has completed an End-of-Phase 2 EOP2 meeting with the FDA for PL9643 for the treatment of dry eye disease DED. Palatin remains on track to initiate the Phase 3 program in DED patients during Q4 of 2021, with data readout expected in 2H of 2022. 